Panax ginseng C. A. MEYER (ginseng) is one of the most common herbal medicines in the Orient used for the treatment of disease. Ginseng saponins (ginsenosides) are the major active components in ginseng and possess anti-inflammatory, anti-cancer, and neuroprotective activity. [1] [2] [3] Of the ginsenosides, Rk1, Rg3, Rg5, F4 2 , etc. are isolated from heat-processed ginseng, Sun Ginseng (SG), but they are not detected in raw or air-dried ginseng. 4, 5) The enhanced antitumor activity of SG is attributed to the generation of ginsenosides due to heat processing. 4, 6) The molecular mechanisms underlying the anti-tumor activity of SG-derived ginsenosides have not been comprehensively investigated.
11)
Phosphorylation of FADD at Ser194 is involved in the G2/M phase arrest in Burkitt lymphoma and breast cancer cells. 12, 13) Members of the mitogen-activated protein kinase (MAPK) family represent one type of serine/threonine protein kinase, and are key modulators of cell activation, including apoptosis and cell cycle progression. To date, three major MAPKs, extracellular-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38, have been identified. ERK is generally activated by growth factors and is involved in the regulation of cell proliferation. 14, 15) Activation of ERK is often associated with cell cycle arrest. 16, 17) In this study, the mechanism underlying the anti-tumor activity of the ginsenoside Rk1 was investigated by examining the effects of Rk1 on cell growth, telomerase activity, and apoptosis in human hepatocellular carcinoma HepG2 cells.
MATERIALS AND METHODS

Chemicals
The ginsenoside Rk1 ( Fig. 1 ) was isolated from SG as previously described 6) and confirmed by NMR and MS spectroscopic analysis. The compound was dissolved in dimethylsulfoxide (DMSO) at a concentration of 20 mM and stored at Ϫ20°C. When required, the compound was diluted with medium to the appropriate concentration.
Cell Culture and Treatment The human hepatocellular carcinoma cell line HepG2 was purchased from the American Type Culture Collection (ATCC). Cells were maintained in Dulbecco's modified Eagle medium (Gibco, NY, U.S.A.) supplemented with 10% fetal bovine serum (Gibco), 100 units/ml penicillin, and 100 mg/ml streptomycin at 37°C in a humidified atmosphere with 5% CO 2 . In this study, the HepG2 cells were incubated in medium with or without Rk1 for 48 h.
Analysis of Cell Viability Cell viability was determined using the Cell Counting Kit-8 (Dojindo Laboratories, Kumamoto, Japan). 18) Briefly, exponentially growing cells were seeded in a 96-well plate at a density of 1.0ϫ10 4 cells/well in triplicate. The next day, the cells were treated with Rk1 at concentrations ranging from 12.5 to 100 mM. After incubation for 48 h, 10 ml of the kit reagent was added and the cells were incubated for an additional 1 h. Cell viability was measured by scanning with a microplate reader at 450 nm. Control cells were exposed to culture media containing 0.5% (v/v) DMSO.
Telomerase Activity Assay Telomerase activity was measured with the PCR-based telomere repeat amplification protocol (TRAP) using the TRAPeze ELISA Telomerase Detection Kit (Chemicon, CA, U.S.A.) as described by the manufacturer. Cells were homogenized in 1X CHAPS lysis buffer containing 200 units/ml of RNase inhibitor on ice for 30 min. Then, 50 ng of each cell extract was analyzed in the TRAP reaction. The cell extracts were added to the reaction mixture containing biotinylated telomerase substrate (TS) primer, biotinylated reverse primer, internal control primers, dATP, dTTP, dGTP, dinitrophenyl (DNP)-labeled dCTP and Taq polymerase, and PCR was performed (primer elongation at 25°C, 30 min; amplification for 33 cycles at 94°C, 30 s; 55°C, 30 s). The level of generated TRAP product was determined by assessing the level of horseradish peroxidase (HRP) activity using the anti-DNP antibody conjugated HRP using a microplate reader at a 450 nm reading wavelength with a 690 nm reference wavelength. Kit-supplied TSR8 and HeLa cell lysate served as positive controls. For the negative controls, extracts from control cells and HeLa cells were heated at 90°C for 10 min. To investigate whether Rk1 interferes directly with telomerase activity, the control cell extract was treated with 100 mM of Rk1 for 10 min at 30°C before initiation of the TRAP process.
Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) Total RNA was extracted using an RNeasy Mini Kit (Qiagen, Gmbh, Germany) according to the manufacturer's protocol. The cDNA was synthesized from 1 mg of total RNA, pretreated with 5 units of RNase-free DNase I (TaKaRa, Shiga, Japan) to remove genomic DNA using Superscript RNase H Ϫ reverse transcriptase (Invitrogen, CA, U.S.A.) and random primers as previously described. 19 ) PCR amplification of hTERT, hTR, and c-Myc was performed with 2 ml cDNA using 1X PCR buffer containing 200 mM dNTP, 1.5 mM MgCl 2 , 200 nM each primer, and 1.25 units Taq DNA polymerase (Promega, WI, U.S.A.). The PCR products were electrophoresed in 6% polyacrylamide gel and visualized on a UV transilluminator by ethidium bromide staining. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control. Primer sequences are shown in Table 1 .
Flow Cytometric Analysis Apoptotic cell death was assessed by annexin-V/PI double staining using an Annexin-V-FLUOS Staining Kit (Roche, Penzberg, Germany) according to the manufacturer's recommendations. Briefly, whole cells were collected, rinsed with PBS, incubated with 100 ml of annexin-V-fluor labeling solution containing 2 ml of annexin-V-FITC and 2 ml of PI at RT for 15 min in the dark, and analyzed by a FACSCalibur flow cytometer. At least 20000 events were evaluated in these experiments.
Western Blot Analysis The cells were lysed using a NucBuster Protein Extraction Kit (Novagen, WI, U.S.A.) supplemented with 1X protease inhibitor cocktail and 1 mM DTT according to the manufacturer's instructions. Wholecell lysates (50 mg/lane) were separated by NuPAGE 4-12% Bis-Tris gel (Invitrogen), blotted onto a PVDF transfer membrane, and then analyzed with the desired antibodies. The bound antibodies were visualized using ECL Plus Western Blotting Detection Reagents (GE Healthcare, Buckinghamshire, U.K.) and LAS-4000 (Fujifilm, Tokyo, Japan). Monoclonal antibodies to GAPDH, caspase-8, and cleaved caspase-8 and polyclonal antibodies to caspase-3, cleaved caspase-3, PARP, FADD, ERK (p44/42 MAP Kinase), phosphorylated ERK (Thr202/Tyr204), caspase-9, Bcl-2, Bcl-xL, Bax, and Puma were purchased from Cell Signaling Technology, Inc. (Cell Signaling, MA, U.S.A.). The antibody to the cleaved form of PARP was obtained from BD Biosciences Pharmingen (BD Biosciences, CA, U.S.A.).
RESULTS
Rk1 Suppresses Cell Growth
To assess the effect of Rk1 on cell viability, HepG2 cells were incubated with Rk1 at 0 to 100 mM. Rk1 suppressed cell growth in a dose-dependent manner ( Fig. 2A) . Rk1-induced cell death was significant at 75 and 100 mM Rk1, resulting in 55 and 95% cell death, respectively. Morphological changes observed by phase-contrast microscopy ( Fig. 2B) showed that cells treated with high concentrations of Rk1 transformed themselves into apoptotic bodies and detached from the culture dish. These findings suggest that Rk1 induces apoptotic cell death through some mechanism.
Rk1 Inhibits Telomerase Activity To examine the effect of Rk1 on telomerase activity, we performed the TRAP-ELISA assay using purified telomerase from HepG2 cells treated with different concentrations of Rk1. Figure 3A shows that Rk1 dramatically inhibits telomerase activity in a dose-dependent manner. In cells exposed to 100 mM Rk1, telomerase activity decreased to 27.8% of that of the control. Investigations into whether Rk1-induced inhibition of telomerase activity was due to direct interference by Rk1 showed that Rk1 did not directly interfere with telomerase, telomeric repeats, or Taq polymerase (Fig. 3B) . Taken together, these 
Rk1 Decreases hTERT and c-Myc mRNA Expression
The mechanism of telomerase inhibition by Rk1 was investigated by assessing the levels of hTR, hTERT, and c-Myc mRNA by RT-PCR (Fig. 4) . hTR and hTERT are the essential components of telomerase, and c-Myc is a regulator of hTERT gene expression. 20) For this analysis, HepG2 cells were treated with 100 mM Rk1, because significant inhibition of telomerase activity was observed at this concentration.
Rk1 treatment decreased hTERT mRNA expression, had no effect on hTR mRNA expression, and markedly suppressed c-Myc mRNA expression. These results show that inhibition of telomerase activity by Rk1 involves down-regulation of c- Myc mRNA expression.
Rk1 Induces Apoptosis through Activation of Caspases-8 and -3, Independent of FADD Expression Annexin-V/PI double staining was used to investigate Rk1-induced apoptotic cell death in HepG2 cells. As shown in Fig.  5 , treatment of HepG2 cells with 100 mM Rk1 induced an increase in the fraction of early apoptotic cells from 0.46 to 16.23%. Western blot analysis was then used to investigate the expression of proteins involved in the apoptotic response to determine if apoptosis occurs via the intrinsic or extrinsic pathway (Fig. 6A) . Both activation of caspase-3 and cleavage of PARP were clearly detected after Rk1 treatment. At the same time, the expression of both procaspase-3 and fulllength PARP decreased. The 18 kDa active form of caspase-8 was also detected on Rk1-treated cells along with a decrease in the expression of procaspase-8. The expression of FADD, upstream of caspase-8, was reduced following Rk1 treatment. Activation of ERK, which occurred through phosphorylation of Thr202 and Tyr204, was significantly enhanced in Rk1-treated cells. 21) The expression levels of Bcl-2, Bcl-xL, Bax, and Puma were also examined, although these proteins are not involved in the apoptotic response (data not shown). In addition, the active form of caspase-9 was not detected after Rk1 treatment (Fig. 6B) . These results suggest that Rk1 induces mitochondria-independent apoptosis through activation of caspase-8, the signaling cascade of which was not associated with FADD expression.
DISCUSSION
Cancer cells are typically distinguished from normal cells by their resistance to apoptosis and the maintenance of telomere integrity through telomerase reactivation. Thus, telomerase is an outstanding cancer marker and a key target for anti-tumor therapy. 22) In particular, hTERT expression is closely associated with telomerase activity. In the liver, hTERT mRNA expression is progressively increased during hepatocarcinogenesis, and a great induction is found in dysplastic nodules. 23) In this study, we found that Rk1 is associated with inhibition of telomerase activity through reduction of hTERT mRNA expression in human hepatocellular carcinoma HepG2 cells.
Caspase-8 activation has been investigated in association with tumor necrosis factor-receptor (TNF-R) family-mediated apoptosis. Oligomerization of caspase-8 is an essential step in the activation process of caspase-8, which generally requires FADD in Fas-dependent apoptosis. 24, 25) However, in the apoptotic response of anticancer drugs, such as mitomycin C and staurosporine, caspase-8 can be activated in the absence of a FADD-containing receptor signaling complex, suggesting that in this case, apoptosis does not require death receptor signaling. 26) Similarly, in Burkitt lymphoma B cells, caspase-8 cleavage and apoptosis are regulated by TGFbmediated p38 activation and appear to be independent of FADD. 27) Another possible mechanism by which downstream caspase-8 is activated is through Raf/ERK signaling, which is independent of FADD expression. 28) Caspase-8-mediated activation of caspase-3 can occur via mitochondria-independent or -dependent pathways. 26) Consistent with previous studies, the results of our study in HepG2 cells demonstrate that Rk1 activates caspase-8 through a FADD-independent apoptotic pathway, which then leads to activation of caspase-3.
The transcription factor c-Myc, a member of the Myc family of b/HLH/LZ proteins, regulates the expression of a number of genes associated with apoptosis, although the mechanism by which this occurs is unclear. c-Myc is one of the direct regulatory elements in the promoter region of hTERT, E-box 29) ; thus, hTERT is a direct target of c-Myc. 30 ) Also, down-regulation of c-Myc appears to induce cell cycle arrest and apoptosis in Jurkat T lymphocytes and acute myeloid leukemia. 31, 32) Interestingly, it has recently been reported that MAPK phosphatase-1 (MKP-1) overexpression might block gene transcription of c-fos, c-myc, and cyclin D1, leading to impaired epithelial proliferation. 33) Brondello et al. showed that MKP-1 was transcriptionally induced through ERK activation. 34) For these reasons, we postulate that Rk1 activates ERK and up-regulates MKP-1, resulting in activation of caspase-8 and down-regulation of c-Myc, respectively. However, further study is needed to characterize the molecular mechanisms underlying the caspase-8 adaptor whose expression might be controlled by ERK activation.
In order to achieve anti-tumor response, it is important to inhibit telomerase activity and to induce apoptosis. An interesting correlation between the inhibition of telomerase activity and c-Myc expression in apoptotic cells has recently been established. Human melanoma cells have been shown to respond to the suppression of c-Myc expression by entering a crisis phase that involves inhibition of telomerase activity, telomere erosion, and apoptosis. 35) In addition, a positive correlation has been reported between inhibition of telomerase activity and apoptosis by curcumin in cancer cells, 36) although the signal activating apoptosis in the telomerase-inhibited cells has not been completely characterized. In this study, it appears that phosphorylation of ERK might be related to inhibition of telomerase and induction of apoptosis, though the connection between telomerase and apoptosis is not clear.
In summary, although the exact mechanism by which activation of ERK induces apoptosis is unclear, the anti-tumor activity of the ginsenoside Rk1 appears to involve inhibition of telomerase activity and the induction of apoptosis. These results highlight Rk1 as a promising therapeutic agent for hepatocellular carcinoma.
